Stocks Health care ORGO
NASDAQ · Health careOrganogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. brought in $352M of revenue over the twelve months to September 30, 2026, down 24.3% from a year earlier. It posted a net loss of $135.4M. In fiscal 2025 capital spending exceeded operating cash flow by $24.5M. At September 30, 2026 it held $21.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Organogenesis Holdings Inc.
- Net worth
- Organogenesis Holdings Inc. has a market value (market cap) of $120.3M at the latest share price, and shareholders' equity of $119.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $564.2M (+17.0% year on year), with net income of $37M. Over the 12 months to September 30, 2026: revenue $352M, net loss $135.4M.
- Cash flow
- In fiscal 2025 operations used $10.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Organogenesis Holdings Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Organogenesis Holdings Inc. does
Organogenesis Holdings Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORGO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $564.2M | $37M | $0.15 | -$24.5M |
| 2024 | $482M | $861K | -$0.01 | $4.2M |
| 2023 | $433.1M | $4.9M | $0.04 | $6.6M |
| 2022 | $450.9M | $15.5M | $0.12 | -$9M |
| 2021 | $467.4M | $94.2M | $0.70 | $30.8M |
| 2020 | $338.3M | $17.2M | $0.15 | -$12.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ORGO ranks in Health care
Latest SEC filings
What Organogenesis Holdings Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 70% to $45.5M versus the same quarter last year; diluted EPS -$0.25 versus $0.11.
- November 5, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 57% to $43.8M versus the same quarter last year; diluted EPS -$0.77 versus -$0.10.
- August 6, 2026
- June 16, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 57% to $37.2M versus the same quarter last year; diluted EPS -$0.44 versus -$0.17.
- May 7, 2026
- April 30, 2026
- April 30, 2026Proxy statement DEF 14A
Insider trades
What the people running Organogenesis Holdings Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 9, 2026 | Driscoll Michael JosephDirector | Bought | 10,000 | $26.7K |
| March 9, 2026 | Leibowitz Arthur SDirector | Bought | 5,000 | $13.4K |
| March 1, 2026 | Cavorsi RobertVice President, Strategy | Shares withheld for tax | 700 | $2.2K |
| February 18, 2026 | Freedman LoriChief Admin. and Legal Officer | Received as pay | 43,212 | - |
| February 18, 2026 | Freedman LoriChief Admin. and Legal Officer | Shares withheld for tax | 14,411 | $55.3K |
| February 18, 2026 | Cavorsi RobertVice President, Strategy | Received as pay | 16,454 | - |
| February 18, 2026 | Cavorsi RobertVice President, Strategy | Shares withheld for tax | 5,487 | $21.1K |
| February 18, 2026 | Francisco DavidChief Financial Officer | Received as pay | 44,040 | - |
Who owns ORGO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Thompson Dean13D, may seek influence with 5 related filers | 18% | November 19, 2024 |
| Alan A. Ades13D, may seek influence with 13 related filers | 17.6% | June 26, 2025 |
| Glenn H. Nussdorf13D, may seek influence with 2 related filers | 9.7% | November 3, 2025 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 7.9% | February 12, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 135 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Morgan Stanley | 11,721,609 | +104,814 |
| Soleus Capital Management, L.P. | 10,140,951 | +55,000 |
| BlackRock, Inc. | 7,249,528 | +2,349,777 |
| Assenagon Asset Management S.A. | 3,935,904 | +1,967,952 |
| Dimensional Fund Advisors LP | 3,050,297 | +159,291 |
| Aqr Capital Management LLC | 3,011,753 | +2,130,036 |
| Vanguard Capital Management LLC | 2,905,919 | +5,103 |
| D. E. Shaw & Co., Inc. | 2,888,313 | +590,339 |
| Geode Capital Management, LLC | 1,935,554 | +151,590 |
| Deutsche Bank AG\ | 1,706,186 | +505 |
| Vanguard Portfolio Management LLC | 1,607,729 | +158,637 |
| State Street Corp | 1,519,955 | -5,153 |
| Renaissance Technologies LLC | 1,017,113 | -51,425 |
| Charles Schwab Investment Management Inc | 905,024 | +25,192 |
| Goldman Sachs Group Inc | 887,399 | +367,049 |
| Citadel Advisors LLC | 867,929 | +323,694 |
| Flax Pond Capital, LLC | 842,682 | +422,591 |
| Jacobs Levy Equity Management, Inc | 692,197 | new |
| Healthcare of Ontario Pension Plan Trust Fund | 628,700 | new |
| Northern Trust Corp | 584,577 | +30,149 |
Insiders
15 insiders reported holding 12,691,113 shares in total, about $11.9M at the last price.
| Holder | Shares |
|---|---|
| Gillheeney Gary S.President and CEO, Director | 4,232,087 |
| Nussdorf Glenn HDirector | 2,565,591 |
| Bilbo PatrickChief Operating Officer | 1,128,312 |
| Freedman LoriChief Admin. and Legal Officer | 1,023,643 |
| Grow BrianChief Commercial Officer | 899,724 |
| Francisco DavidChief Financial Officer | 731,312 |
| Leibowitz Arthur SDirector | 291,014 |
| Cavorsi RobertVice President, Strategy | 275,524 |
| Duraibabu PrathyushaDirector | 247,047 |
| Giacomin Jon LDirector | 241,026 |
Questions about ORGO
What does Organogenesis Holdings Inc. do?
Organogenesis Holdings Inc. is a company in the Health care sector, listed on NASDAQ as ORGO. Its shares trade on NASDAQ under the ticker ORGO.
What is Organogenesis Holdings Inc.'s net worth?
Organogenesis Holdings Inc. has a market value (market cap) of $120.3M at the latest share price, and shareholders' equity of $119.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Organogenesis Holdings Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $135.4M on revenue of $352M.
How much revenue does Organogenesis Holdings Inc. make?
Over the twelve months to September 30, 2026 Organogenesis Holdings Inc. reported revenue of $352M. That is 24.3% less than a year earlier.
When did Organogenesis Holdings Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Organogenesis Holdings Inc.'s next earnings report?
Organogenesis Holdings Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ORGO with
Follow ORGO
Get an email when Organogenesis Holdings Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Organogenesis Holdings Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.